Selected article for: "admission day and leukocyte count"

Author: Shi, Miao-yan; Sun, Shi-qi; Zhang, Wei; Zhang, Xing; Xu, Gui-hua; Chen, Xuan; Su, Zi-jian; Song, Xiu-ming; Liu, Lu-jiong; Zhang, Yi-bao; Zhang, Yi-le; Sun, Meng; Chen, Qi; Xue, Yan; Lü, Hua; Yuan, Wei-an; Chen, Xiao-rong; Lu, Yun-fei
Title: Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: a retrospective cohort study
  • Cord-id: 7ufe4gmw
  • Document date: 2021_1_13
  • ID: 7ufe4gmw
    Snippet: OBJECTIVE: To observe the early interventions of traditional Chinese Medicine (TCM) on the conversion time of nucleic acid in patients with coronavirus disease 2019 (COVID-19), and find possible underlying mechanisms of action. METHODS: A retrospective cohort study was conducted on 300 confirmed COVID-19 patients who were treated with TCM, at a designated hospital in China. The patients were categorized into three groups: TCM1, TCM2 and TCM3, who respectively received TCM interventions within 7,
    Document: OBJECTIVE: To observe the early interventions of traditional Chinese Medicine (TCM) on the conversion time of nucleic acid in patients with coronavirus disease 2019 (COVID-19), and find possible underlying mechanisms of action. METHODS: A retrospective cohort study was conducted on 300 confirmed COVID-19 patients who were treated with TCM, at a designated hospital in China. The patients were categorized into three groups: TCM1, TCM2 and TCM3, who respectively received TCM interventions within 7, 8–14, and greater than 15 days of hospitalization. Different indicators such as the conversion time of pharyngeal swab nucleic acid, the conversion time of fecal nucleic acid, length of hospital stay, and inflammatory markers (leukocyte count, and lymphocyte count and percentage) were analyzed to observe the impact of early TCM interventions on these groups. RESULTS: The median conversion times of pharyngeal swab nucleic acid in the three groups were 5.5, 7 and 16 d (P < 0.001), with TCM1 and TCM2 being statistically different from TCM3 (P < 0.01). TCM1 (P < 0.05) and TCM3 (P < 0.01) were statistically different from TCM2. The median conversion times of fecal nucleic acid in the three groups were 7, 9 and 17 d (P < 0.001). Conversion times of fecal nucleic acid in TCM1 were statistically different from TCM3 and TCM2 (P < 0.01). The median lengths of hospital stay in the three groups were 13, 16 and 21 d (P < 0.001). TCM1 and TCM2 were statistically different from TCM3 (P < 0.01); TCM1 and TCM3 were statistically different from TCM2 (P < 0.01). Both leucocyte and lymphocyte counts increased gradually with an increase in the length of hospital stay in TCM1 group patients, with a statistically significant difference observed at each time point in the group (P < 0.001). Statistically significant differences in lymphocyte count and percentage in TCM2 (P < 0.001), and in leucocyte count (P = 0.043) and lymphocyte count (P = 0.038) in TCM3 were observed. The comparison among the three groups showed a statistically significant difference in lymphocyte percentage on the third day of admission (P = 0.044). CONCLUSION: In this study, it was observed that in COVID-19 patients treated with a combination of Chinese and Western medicines, TCM intervention earlier in the hospital stay correlated with faster conversion time of pharyngeal swab and fecal nucleic acid, as well as shorter length of hospital stay, thus helping promote faster recovery of the patient. The underlying mechanism of action may be related to improving inflammation in patients with COVID-19. Please cite this article as: Shi MY, Sun SQ, Zhang W, Zhang X, Xu GH, Chen X, Su ZJ, Song XM, Liu LJ, Zhang YB, Zhang YL, Sun M, Chen Q, Xue Y, Lü H, Yuan WA, Chen XR, Lu YF. Early therapeutic interventions of traditional Chinese Medicine in COVID-19 patients: a retrospective cohort study. J Integr Med. 2021; Epub ahead of print.

    Search related documents:
    Co phrase search for related documents
    • acid base electrolyte and lopinavir ritonavir: 1, 2, 3
    • acid base electrolyte balance and acute respiratory: 1, 2
    • acid base electrolyte balance and lopinavir ritonavir: 1, 2, 3
    • acid testing and active treatment: 1, 2, 3, 4, 5, 6, 7
    • acid testing and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid testing and acute respiratory tract: 1, 2
    • acid testing and admission disease: 1, 2
    • acid testing and admission disease onset: 1
    • acid testing and admission fever: 1
    • acid testing and admission time: 1, 2, 3, 4, 5
    • acid testing and lopinavir ritonavir: 1, 2, 3, 4
    • acid testing and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active treatment and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active treatment and acute respiratory tract: 1, 2
    • active treatment and admission disease: 1, 2, 3
    • active treatment and admission fever: 1
    • active treatment and long history: 1
    • active treatment and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8
    • active treatment and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9